Abstract

TNNI3 encoding cTnI, the inhibitory subunit of the troponin complex, is the main target for mutations leading to restrictive cardiomyopathy (RCM). Here we investigate two cTnI-R170G/W amino acid replacements, identified in infantile RCM patients, which are located in the regulatory C-terminus of cTnI. The C-terminus is thought to modulate the function of the inhibitory region of cTnI. Both cTnI-R170G/W strongly enhanced the Ca2+-sensitivity of skinned fibres, as is typical for RCM-mutations. Both mutants strongly enhanced the affinity of troponin (cTn) to tropomyosin compared to wildtype cTn, whereas binding to actin was either strengthened (R170G) or weakened (R170W). Furthermore, the stability of reconstituted thin filaments was reduced as revealed by electron microscopy. Filaments containing R170G/W appeared wavy and showed breaks. Decoration of filaments with myosin subfragment S1 was normal in the presence of R170W, but was irregular with R170G. Surprisingly, both mutants did not affect the Ca2+-dependent activation of reconstituted cardiac thin filaments. In the presence of the N-terminal fragment of cardiac myosin binding protein C (cMyBPC-C0C2) cooperativity of thin filament activation was increased only when the filaments contained wildtype cTn. No effect was observed in the presence of cTn containing R170G/W. cMyBPC-C0C2 significantly reduced binding of wildtype troponin to actin/tropomyosin, but not of both mutant cTn. Moreover, we found a direct troponin/cMyBPC-C0C2 interaction using microscale thermophoresis and identified cTnI and cTnT, but not cTnC as binding partners for cMyBPC-C0C2. Only cTn containing cTnI-R170G showed a reduced affinity towards cMyBPC-C0C2. Our results suggest that the RCM cTnI variants R170G/W impair the communication between thin and thick filament proteins and destabilize thin filaments.

Highlights

  • Cardiac troponin I, the inhibitory subunit of the heterotrimeric troponin complex, plays a key role in inhibiting the actin-myosin interaction during diastole

  • Both TNNI3 variants were not found in gnomAD exome and gnomAD genome databases, but were reported in ClinVar in association with cardiomyopathy and revealed high probability of damaging effect using MutationTester, SIFT, PROVEAN and MetaSVM prediction tools

  • No familial history of cardiac disorders was reported in the R170W case, parental testing confirmed that the R170W variant occurred de novo

Read more

Summary

Introduction

Cardiac troponin I (cTnI), the inhibitory subunit of the heterotrimeric troponin complex (cTn), plays a key role in inhibiting the actin-myosin interaction during diastole. Inhibition is abrogated during systole in response to the increase in cytosolic calcium ion (Ca2+) concentration and saturation of the Ca2+-binding subunit (cTnC) with Ca2+. This event leads to a series of conformational changes: the regulatory C-terminal region of cTnI is released from tropomyosin/actin, allowing after an azimuthal movement of tropomyosin the actin-myosin interaction. The molecular mechanisms are not yet fully elucidated. It is unknown how cardiomyopathy inducing mutations affect this interplay

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call